Over the past few decades, the survival of esophageal cancer patients has improved owing to early detection and advances in multimodality treatment strategies. Imaging plays an important role in every step in the management of esophageal cancer, including diagnosis, staging, assessment of treatment response, and post-treatment surveillance. In this article, we provide a comprehensive review of the role of imaging in these various time points of esophageal cancer management.
Esophageal cancer is the eighth most common cancer in the world [1] . In the United States, it is estimated that 16,980 people will be diagnosed with new esophageal cancer in the year 2015 and about 15,590 deaths will be attributable to it in the due course [2] . The overall prognosis of esophageal cancer is poor, with 14% 10-year survival [3] . The median survival drops from 35 months for patients with local disease to 6 months for patients with metastatic disease [3] . However, a recent analysis of the Surveillance Epidemiology and End Results (SEER) database between 1973 and 2007 has shown that there has been gradual increase in the cure rates of all stages of esophageal cancer with consequent increase in survival [3] . The median survival of local esophageal cancer has increased from 11 months in 1970s to 35 months after 2000 [3] .
The optimal management of esophageal cancer is largely determined by the stage of the disease, performance status of the patient and the location of the tumour [4] . The last few decades have seen a paradigm shift in the esophageal cancer staging and management. There have been major changes in the way esophageal cancer is staged in the 2010 revised TNM staging of American Joint Committee on Cancer (AJCC) [5] . From a treatment point of view, the oncologists now routinely employ neoadjuvant chemoradiotherapy followed by curative surgery and adjuvant systemic chemotherapy [6] . Trastuzumab, the monoclonocal antibody against human epidermal growth factor receptor2 (HER2neu) receptor, which is overexpressed in esophageal adenocarcinoma has been shown to significantly improve the overall survival of patients with HER2-neu receptor over expression [7] . New molecular targeted drugs like inhibitors of vascular endothelial growth factor (VEGF) and epidermal growth factor receptors (EGFR) are under research for advanced and metastatic esophageal cancer [8e12] .
In this context, the proper selection of patients for appropriate treatment strategies becomes important. The corner stone for appropriate patient selection in esophageal cancer is imagingdendoscopic ultrasonography (EUS), multidetector computed tomography (MDCT), and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). Each of these modalities has a specific role in each component of the TNM staging. The assessment of treatment response as determined by imaging is also crucial in treatment planning. Accordingly the aim of this article is to provide a comprehensive review of the role of imaging in the initial staging and subsequent management of esophageal carcinoma.
Epidemiology, Etiopathogenesis, and Pathology
Squamous cell carcinoma (SCC) is the most common type of esophageal cancer but has a great degree of geographic variation in its incidence with very high incidence rates seen in eastern countries such as China [8] . Risk factors for SCC include alcohol abuse, smoking, human papilloma virus (HPV) infection, achalasia, PlummereVinson syndrome, and celiac disease [13] . SCC typically occurs in the middle and lower third of the esophagus, with only 10%-15% occurring in the upper one-third segment [8] (Figure 1 ). Grossly, SCC can have fungating, ulcerative, or infiltrating growth patterns.
Though SCC is the most common type of esophageal malignancy, there has been a dramatic increase in the incidence of adenocarcinoma, especially among white men and women [14] . Risk factors for adenocarcinoma include obesity, chronic gastroesophageal reflux, and Barrett's esophagus. There is a higher male preponderance for adenocarcinoma than SCC [14] . Adenocarcinoma typically arises from the metaplastic columnar epithelium in the lower third of the esophagus especially esophagogastric junction [6] . At a molecular level, esophageal adenocarcinomas have more frequent HER2-neu gene amplification and overexpression than SCC [6] At gross histopathology, adenocarcinomas are predominantly ulcerated, flat lesions with only 33% of the tumours having a polypoidal or fungating growth patterns [8] (Figure 2 ).
Revised Tumor, Node, Metastasis (TNM) Staging of Esophageal Cancer (2010)
Esophageal cancer is staged according to the International Union Against Cancer and AJCC TNM staging [5] . There have been changes in all the components of TNM staging in the revised 2010 AJCC staging system. The availability of extensive data pertaining to the association of histopathologic type and survival formed the basis for the revisions in the staging system. Distinct staging systems have been proposed for esophageal adenocarcinoma and SCC in the new AJCC staging. The T stage is determined by the depth of invasion of the esophageal wall (T1-4). The criteria for subdivisions in T4 tumours has been revised in the new TNM (2010) staging system: T4a tumours invade the pericardium, pleura, or diaphragm and are potentially resectable, whereas T4b tumours invade the heart, aorta, trachea, and other great vessels, and are unresectable ( Figure 3 ). The N stage has been subdivided into N1-N3 based on the number of lymph nodes. This is based on the evidence that the number of positive nodes is a significant prognostic factor. N1 refers to metastases in 1-2 regional nodes, N2 metastases in 3-6 regional nodes, and N3 metastases in 7 or more regional nodes. In the revised TNM staging the subclassification of M into M1a and M1b has been amended as this was not found to be of prognostic significance. M stage is determined by the presence (M1) or absence (M0) of metastatic disease including metastases in the nonregional nodes.
Tumours of the Gastroesophageal Junction
The nomenclature of the tumours of the gastroesophageal junction (GEJ) is controversial. The modified Siewert classification includes three types of tumours [6, 15] . Type I tumours are distal esophageal adenocarcinomas located within 1-5 cm above the GEJ. Type II tumours are adenocarcinomas of the gastric cardia with in 1 cm above the GEJ and 2 cm below the GEJ (Figure 4 ). Type III tumours are tumours below the gastric cardia between 2 cm and 5 cm from the GEJ. According to the new AJCC staging tumours with epicenter in the distal esophagus, GEJ and in the proximal 5 cm of stomach extending into the GEJ or esophagus are staged as esophageal cancer. In contrast, tumours 5 cm beyond the GEJ in the stomach and tumours in the proximal 5 cm of stomach not extending in to the GEJ or esophagus are staged as gastric cancers [5] . mass to be FDG-avid on the pretreatment scan (D) with significant decrease in FDG avidity on the post-treatment scan (E) There is FDG uptake in the esophagus proximal to the tumour and in the stomach. This uptake mimics residual tumour but represents post radiotherapy inflammation, which was confirmed at endoscopic biopsy. This figure is available in colour online at http://carjonline.org/.
Staging of Primary Esophageal Carcinoma (T): Role of Imaging
SCC and adenocarcinoma cannot be differentiated on imaging. On conventional barium esophagography, esophageal carcinoma is seen as irregular short-segment stricture with proximal shouldering, polypoidal intraluminal filling defects, and irregular mucosal ulceration [13] ( Figure 5 ). Extravasation of the contrast into the mediastinum or the trachea can be seen in cases of malignant esophageal perforation or trachea-esophageal fistula.
TNM staging of esophageal carcinoma requires comprehensive evaluation with EUS, MDCT, and FDG-PET/CT.
Endoscopic Ultrasound
T staging is determined by the depth of penetration of the esophageal wall and is best assessed by EUS. EUS uses endoscopic sonographic transducers (7.5-12 MHz) to define the various layers of the esophageal wall. EUS helps in differentiating T1/T2 tumours, which are treated with surgical resection from T3/T4 tumours, which need preoperative chemoradiotherapy (CRT); the accuracy of staging increases with the depth of invasion ( Figure 2 ). In a meta-analysis of 49 studies, EUS had excellent sensitivity and specificity for accurately staging esophageal cancer, but had better performance in T4 (pooled sensitivity/specificity of 92% and 97%, respectively) than T1 (pooled sensitivity/specificity of 82% and 99%, respectively) tumours [16] . Limitations of EUS include operator dependency, suboptimal evaluation of stenotic tumours, and risk of perforation.
MDCT
MDCT plays an important role in excluding T3 and T4 disease by excluding local invasion. T3 disease is seen on MDCT as periesophageal fat infiltration, whereas T4 disease is seen as loss of fat planes between the tumour and adjacent mediastinal structure with or without displacement or indentation ( Figure 3 ) [17] . Aortic invasion is suspected if the contact between the aorta and the tumour is more than 90 or when the triangular fat between esophagus, aorta, and spine is obliterated [17] . Tracheobronchial invasion is suggested by indentation of the tracheal or bronchial wall by the tumour or by presence of tracheoesophageal fistula. Advantages of MDCT include multiplanar reformations, which allow assessment of tumour length and tumours at GEJ [17] . Limitations include inability to stage T1/T2 tumours.
Sensitivity/specificity of CT for detecting T3 and T4 disease are 75%/78% and 75%/86%, respectively [18] .
PET/CT
Though PET/CT has higher sensitivity for detecting esophageal cancer, it has limited role in T staging other than determining mediastinal organ invasion [4] . PET/CT has limited ability to differentiate T1, T2, and T3 tumours. Few studies have shown that SCC tend to be more FDG-avid than adenocarcinomas. PET/CT can help in detecting occult primary in patients with metastatic disease at presentation ( Figure 6 ).
Management of Primary Esophageal Carcinoma: Role of Imaging in the Assessment of Treatment Response
The standard treatment for superficial T1 tumours is esophagectomy with endoscopic mucosal resection or ablation reserved for tumours confined to the mucosa [19] . For cervical and upper thoracic esophageal tumours concurrent chemoradiation is recommended [20] . The options for locally advanced esophageal cancer include preoperative chemoradiation, definitive chemoradiation, perioperative chemotherapy (for adenocarcinomas), or esophagectomy [6] . Adjuvant treatment following preoperative or definitive chemoradiation is based on response assessment on imaging (usually PET/CT) or endoscopy. The various adjuvant treatment options include esophagectomy or observation in patients with no residual disease and salvage esophagectomy or palliative therapy for those with persistent disease. Postoperative treatment in patients undergoing esophagectomy depends on the resection margin, nodes, histology and preoperative treatment status [6] .
Commonly used chemotherapeutic drugs in esophageal cancer include 5-flurouracil (5-FU), capecitabine, irinotecan, cisplatin, oxaliplatin, carboplatin, epirubacin, paclitaxel, and docetaxel. Of these, the most commonly used two-drug regimen is 5-FU and cisplatin with addition of docetaxel or epirubacin reserved for patients with good performance status [6, 21] . The NCCN guidelines recommend the addition of trastuzumab for advanced or metastatic adenocarcinomas overexpressing HER2-neu receptors [6] . A variety of targeted therapies including inhibitors of VEGF and EGFR are under research for advanced and metastatic esophageal cancer [9e12, 22] .
Neoadjuvant chemoradiotherapy is now a standard practice in localized esophageal cancer. Several studies have shown that a complete pathologic response to neoadjuvant chemoradiotherapy was the single predictor of survival in patients with locoregional esophageal carcinoma [23e26]. The degree of tumour regression after neoadjuvant treatment is a major predictor of disease-free survival; Chirieac et al [27] , using a tumour regression grading system based on the percentage of residual tumour, found that the overall survival (OS) was significantly better for patients with no residual cancer compared to patients with 1%-10%, 11%-50%, and >50% residual tumour [27] . In the radiologic assessment of treatment response, each imaging modality has advantages and pitfalls. CT and EUS assess response based on morphological changes, which have the potential pitfall of both over and under staging the response. CT is easily available and widely used, however cannot differentiate viable tumour and reactive changes [17] . EUS cannot differentiate residual tumour from fibrosis or necrosis, cannot detect microscopic residual tumour and distant metastases.
PET/CT is a promising tool for assessing treatment response and as a prognostic indicator, though the results have been conflicting in some studies (Figure 7) . Levine et al. [28] in 64 patients with localized esophageal cancer found that a pretreatment standardized uptake value (SUV) of >15 and a post-treatment drop of SUV by >10 were associated with a significant pathologic response in 78% (P ¼ .005) and 71% (P ¼ .004) patients respectively. The cutoff values of SUV and the timing of PET/CT after treatment are not standardized. In the MUNICON II trial of 110 patients with locally advanced esophageal cancer, a SUV drop of 35% after 2 weeks of treatment was associated with a better OS. The timing of the PET/CT after radiotherapy may affect the accuracy of PET/CT in determining response [29] . Pitfalls in the interpretation of post-therapy PET/CT occur in the setting of postradiation esophagitis and biopsy associated inflammation, which can mask the drop in SUV. It is therefore recommended to perform post treatment PET/CT as early as two weeks after treatment and before any repeat biopsies [30] (Figure 2 ). Because PET/CT cannot detect microscopic residual disease, the National Comprehensive Cancer Network guidelines do not recommend PET/CT to select patients for surgery after chemoradiation [6] .
Patterns of Tumour Spread
Esophageal carcinoma, owing to aggressive growth and the lack of anatomic barrier of serosa, has the propensity to spread locally through the esophageal wall into surrounding loose connective tissue and organs such as trachea, bronchi, lung, thyroid gland, aorta, and pericardium. Distal esophageal cancers frequently extend into proximal stomach. Esophagus is also supplied richly by lymphatic and blood supply, which facilitates spread through lymphatics and hematogenous route. Most of the lymphatics from upper twothirds drain into upper mediastinum and lymphatics from the lower third drain into lower mediastinum and abdomen [17] . However, the presence of extensive collateral lymphatic = drainage facilitates spread of cancer of any part of esophagus to any regional nodal basin (Figure 4) . A characteristic feature of SCC is the occurrence of intramural metastases, which is encountered in up to 16% cases and usually associated with advanced stage and poor survival [8] . These intramural metastases are satellite/skip lesions that result from lymphatic spread. Hematogeneous metastases from esophageal cancer most commonly occur in the lung and liver [30] (Figures 1 and 8) . Uncommon sites of spread include bones, adrenal glands, and kidneys [8] (Figure 9 ). Rare sites include brain, subcutaneous soft tissues, skeletal muscles, biliary tree, thyroid gland, and pancreas [31] ( Figures 4 and 10) .
Imaging of Nodal and Distant Metastases
Nodal staging refers to the status of the locoregional nodes that are best evaluated with both EUS and CT. The regional nodes vary with the location of the primary tumour: for the cervical esophagus the regional nodes are the scalene, internal jugular, cervical, supraclavicular, and periesophaeal nodes (Figure 1) ; for the intrathoracic esophagus they are the upper and lower periesophageal and subcarinal nodes; for the intraabdominal esophagus they are the lower esophageal, diaphragmatic, pericardial, left gastric, and celiac nodes [4] (Figure 4 ). Presence of celiac nodal metastases is considered regional nodal metastases irrespective of the location or histology of the primary tumour according to the new AJCC TNM staging (2010) (Figure 4 ). CT can reliably detect enlarged nodes and has sensitivity and specificity of 30%-60% and 60%-80% respectively for nodes greater than 1 cm [4, 17, 18] . The low sensitivity of CT usually does not affect management as the presence of regional nodal metastases does not preclude surgical resection. The sensitivity and specificity of EUS for detecting metastatic nodes is high (85% each) [16] ( Figure 2 ). The addition of EUS-guided fine needle aspiration biopsy increases the sensitivity of N staging from 85%-97% [16] . PET/CT, though has low sensitivity and specificity (51% and 84% respectively) in regional nodal assessment as these nodes are often obscured by the metabolic activity in the primary tumour [32] (Figure 2 ) but can help in detecting nonenlarged metastatic nodes away from the primary tumour (Figure 4 ). Metastases staging refers to distant metastases either to nonregional nodes or to distant sites. Contrast-enhanced CT is the most widely used modality for detecting distant metastases in esophageal cancer, especially for those in the liver and lungs (Figures 1 and 8 ). However, for assessing nonregional nodes, EUS combined with fine needle aspiration biopsy with sensitivity and specificity of 53%-98% and 77%-100% respectively, is the most reliable method [4] . PET/CT is an important addition to the staging algorithm due to its ability to detect metastases, which can remain occult on CT, thereby allowing proper patient selection for surgical resection (Figure 1 ). PET has sensitivity of 71% and specificity of 93% for detecting distant metastases [33] . In a prospective multicenter trial of 129 patients with esophageal cancer, PET identified additional metastatic sites in 41% cases and altered management in 38% cases [34] . PET can also detect synchronous malignancy in 8% of patients (18) .
Management of Metastatic Esophageal Carcinoma: Role of Imaging in the Assessment of Treatment Response
The management of advanced and metastatic esophageal carcinoma depends on the performance status of the patients. In patients with good performance status, combination chemotherapy is preferred over single drug regimen [6] . The commonly used combination regimens include epirubicin, cisplatin, and infusional 5-FU; docetaxel, cisplatin, infusional 5-FU; and epirubicin, oxaliplatin, and capecitabine [6] . There is no established second-or third-line therapy for advanced/metastatic esophageal cancer. The addition of trastuzumab to chemotherapy in suitable candidates is recommended for metastatic esophagogastric adenocarcinomas with immunohistochemistry positive HER2 gene amplification [6] . Lapatinib, an oral small molecule inhibitor of EGFR I and II, has been shown to increase the progression free survival in some studies. Monoclonal anti-EGFR antibodies such as cetuximab and panitumumab, anti-VEGF antibodies such as bevacizumab, and small molecule inhibitors of EGFR and VEGF such as geftinib, erlotinib, and sorafenib are under research for advanced/metastatic esophageal cancer [8,10,12,35e37] .
The duration of first-line chemotherapy in advanced/ metastatic esophageal cancer is determined by a combination of radiologic response, serum tumour marker assessment like carcinoembryonic antigen and overall clinical picture of the patient. The clinical status of the patient usually determines the continuation of therapy [6] . In patients who appear to derive clinical benefit, the treatment can be continued even in the presence of radiologic progression. The response of metastatic lesions in esophageal cancer is assessed using the Response Evaluation Criteria in Solid Tumours 1.1 criteria. However, in our experience, similar to the response of colorectal liver metastasis, response of liver metastases from esophageal cancer can take the form of decrease in density and development of sharp tumour-liver interface with or without concurrent changes in size [38] . These atypical changes of treatment response may be expected to increase in the future due to the anticipated increase in the molecular targeted therapies in the future. Similar to the primary tumours, response of metastatic disease on FDG-PET/CT consists of decrease in FDG uptake.
Conclusion
Imaging plays pivotal role in the selection of treatment strategies in patients with esophageal cancer. CT, EUS, and PET/CT have a specific role in the staging and are usually complimentary. Local staging is usually best done with a combination of CT and EUS while distant and occult metastatic disease is best assessed with PET/CT. Assessment of treatment response of primary tumour with PET/CT has both therapeutic and prognostic significance. Knowledge of the strengths and pitfalls of each modality helps radiologists to guide the oncologists and the surgeons in appropriate patient management. Figure 10 . A 73-year-old woman with moderately differentiated adenocarcinoma of the esophagus. Axial postgadolinium fat-suppressed T1-weighted magnetic resonance image of the brain demonstrates a large heterogeneously enhancing metastatic deposit in the right parietal lobe (arrows) with midline shift.
